Fig. 4

In vivo imaging, in vivo ¹³¹I therapy, and survival analysis. a SPECT/CT fused and three-dimension images of ATC tumor-bearing mice obtained at different time points after intratumoral injection with the respective drugs. The radioactive accumulation in the Na¹³¹I group was not seen at 3 days post-injection, but was obvious even at 3 weeks post-injection in the anti-VEGFR2 targeted group. Tumor volume (b), body weight (c) changes, and Kaplan–Meier survival curves (d) in the FRO ATC xenograft models (n = 6/group). Tumor growth and body weight loss in the targeted group were significantly inhibited compared with those in the non-targeted, Na¹³¹I, or saline group, respectively. Data are presented as the mean ± SD of three groups and all were P < 0.05. Additionally, the median survival time in the targeted group (41 days) was significantly prolonged compared with that in the non-targeted (34 days) or Na¹³¹I (25 days) group (all P < 0.01)